Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Cancer Type, Treatment (Surgery, Chemotherapy, Radiation therapy, Targeted therapy), Diagnostics, and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
CAGR: 6.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The market studied is majorly driven by the factors such as the increasing prevalence of pancreatic cancer, increasing demand for diagnostic tests and treatment of this disease. As a result, many governments and non-profit organizations have taken initiatives to spread awareness regarding pancreatic cancer in the Asia-Pacific region. Moreover, technological advancements have in diagnostics and treatment have led to solutions that more efficient. These are the major factors that have propelled the market growth.

The high cost of treatment and diagnostics and side effects due to therapies is expected to restrain the market growth.

Scope of the Report

Pancreatic cancer happens when uncontrolled cell growth begins in a part of the pancreas. Tumors develop, and these interfere with the way the pancreas works. pancreatic cancer therapeutics and diagnostics involve procedures for successful diagnosis and treatment of the pancreatic cancer.

In the report, a detailed analysis of the Asia-pacific pancreatic cancer therapeutics and diagnostics market is provided. The market is evaluated by collating revenues generated across segments, categorized by Cancer Type, Treatment, Diagnostics, and Geography.

By Type
By Treatment
Radiation Therapy
Targeted Therapy
By Diagnostics
Other Diagnostic Tests
By Cancer Type
Exocrine Cancers
Endocrine Cancers
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

Key Market Trends

Radiotherapy is Expected to register a High CAGR

Radiation therapy is a cancer treatment that uses high-energy radiation, in the form of waves, such as x-rays, or particles, such as protons, to kill cancer cells or prevent them from growing and dividing. Radiation therapy can prevent pancreatic tumors from growing and sometimes shrinks them. Since radiation therapy is directed to a specific (focused) area, it is considered a local treatment.

The demand for radiation therapy in Asia-pacific is also expected to increase as stated by the 2018 report by Noorazrul Yahya et al., published in the Asia-pacific Journal of Clinical Oncology. According to the estimates of the report, the number of radiotherapy fractions needed in 2025 and 2035 is expected to increase to 11.1 million and 14.1 million, respectively, compared to 7.6 million in 2015 in Southeast Asia.

As the demand for increases, it is expected that its application in pancreatic cancer will also increase. This is expected to help the market growth in the region.


Competitive Landscape

Most of the countries in Asia-pacific are developing countries. These developing economies have an increasing prevalence of panreatic cancer. As a result, these countries are highly lucrative for global players to enter the market. Hence, this region enjoys the presence of themost of the global player in the pancreatic cancer therapeutics and diagnostics market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer

      2. 4.2.2 Rising Awareness and Concern about the Disease

      3. 4.2.3 Technological Advancements and Innovation of New Products

    3. 4.3 Market Restraints

      1. 4.3.1 High Costs Associated with Treatment and Diagnosis

      2. 4.3.2 Side Effects of Pancreatic Cancer Therapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 By Treatment

        1. Surgery

        2. Chemotherapy

        3. Radiation Therapy

        4. Targeted Therapy

      2. 5.1.2 By Diagnostics

        1. Imaging

        2. Biopsy

        3. Endoscopy

        4. Other Diagnostic Tests

    2. 5.2 By Cancer Type

      1. 5.2.1 Exocrine Cancers

      2. 5.2.2 Endocrine Cancers

    3. 5.3 Geography

      1. 5.3.1 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific


    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb

      2. 6.1.2 Canon Medical Systems

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche AG

      5. 6.1.5 GE Healthcare

      6. 6.1.6 Hitachi Medical

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc

      9. 6.1.9 Philips Healthcare

      10. 6.1.10 Siemens AG

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 6.4% over the next 5 years.

Bristol-Myers Squibb, Novartis AG, F. Hoffmann-La Roche AG, Pfizer Inc, Eli Lilly and Company are the major companies operating in Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!